Screenshots and collages by Harvard Magazine
And now the pandemic has forced another tradition, nearly sacrosanct, to yield, at least slightly. Harvard has always insisted that honorary-degree recipients be present on campus to receive their accolades (none were conferred last year). But given this second consecutive online ceremony, those recognitions and conferrals will proceed remotely too.
During the May 27 proceedings, “Honoring the Harvard Class of 2021” (as the graduation is being called, since the classes of 2020 and 2021 have been promised a future in-person
Commencement), scheduled to begin at 10:30 a.m., Harvard plans to confer honorary degrees on four women and three men. Ordinarily, the principal speaker of the day would receive an honorary degree as well, but this year’s guest, Ruth J. Simmons, Ph.D. ’73, LL.D. ’02 president emerita of Smith College and Brown University, now president of Prairie View A&M already has one (“Opening minds, opening door
Wozniak or “Woz,” as he was commonly known was the son of an electrical engineer for the Lockheed Missiles and Space Company in Sunnyvale, California, in what would become known as Silicon Valley. A precocious but undisciplined student with a gift for mathematics and an interest in electronics, he attended the University of Colorado at Boulder for one year (1968–69) before dropping out. Following his return to California, he attended a local community college and then the University of California, Berkeley. In 1971 Wozniak designed the “Blue Box,” a device for phreaking (hacking into the telephone network without paying for long-distance calls) that he and Jobs, a student at his old high school whom he met about this time, began selling to other students. Also during the early 1970s Wozniak worked at several small electronics firms in the San Francisco Bay area before obtaining a position with the Hewlett-Packard Company in 1975, by which time he had formally dropped out of
Helen Murray Free with her husband and scientific collaborator Alfred in 1955
Credit: BAYER
Helen Murray Free, who has died aged 98, was the co-developer, with her husband Alfred Free, of Clinistix, the first dip-and-read diagnostic test for diabetes and for monitoring glucose levels in urine, an achievement that revolutionised diagnostic testing.
Before the introduction of Clinistix in 1956, laboratory technicians tested for diabetes by adding a reagent to urine in a test tube and then heating the mixture over a Bunsen burner, a process that was not only cumbersome but also imprecise because it could not distinguish glucose from other sugars.
Working at Miles Laboratories in Indiana, the Frees worked out how to impregnate thin strips of filter paper with chemicals that changed colour based on the concentration of glucose present in the urine, the intensity of the resulting blue-green depending on the amount of peroxide, and hence, glucose, in the sample.
Share:
ISELIN, N.J., May 12, 2021 (GLOBE NEWSWIRE) Outlook Therapeutics, Inc. (NASDAQ:OTLK), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will host a Virtual Clinical Day for analysts and accredited institutional investors with live video webcast (details below) on Thursday, May 20, 2021 from 11:00 AM – 1:00 PM ET.
During the Virtual Clinical Day, Outlook Therapeutics will provide an overview of its lead program, ONS-5010 / LYTENAVA™ (bevacizumab-vikg), its investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), its ongoing Phase 3 study in wet AMD, NORSE TWO, and its plans for a potential commercial rollout.